ClinicalTrials.gg
Active, not recruitingNCT06004986DUPI REDUCEUpdated Oct 29, 2026

DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema

A Phase 4 interventional study of Dupilumab in Atopic Dermatitis and Atopic Dermatitis Eczema, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Active, not recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Phase 4, Interventional, and Treatment

How we know · 3 judgments

Updated Oct 29, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Planned enrollment
14th of 50
216 · median 75
Started
2023
with 6 others
Phase 4
24 of 50
4 open now
Registered
46th of 50
by date
Lead sponsor
1 of 50
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 14th largest by planned enrollment, is one of 7 that started in 2023, is one of 24 in phase 4, and was the 46th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. Researchers will then compare the outcomes among these three groups.

Read the detailed description

While dupilumab is an effective treatment for atopic eczema, it is expensive and not without the risk of unwanted adverse events. Aiming for the lowest possible dose is important. The currently approved dose is a single loading dose of 600 mg, followed by 300 mg every 2 weeks. However, there is evidence that the intervals between doses could be extended in disease-controlled patients while maintaining the same effectiveness. The objective of this study is to assess the (cost)effectiveness and safety of dupilumab dose reduction in patients with controlled atopic eczema. A multicenter, single-blinded, non-inferiority randomized controlled trial will be performed, that is embedded in the TREatment of ATopic eczema (TREAT) NL registry. Adult patients who are already undergoing dupilumab treatment and meet the Treat-to-Target criteria will be assigned randomly to one of three groups: receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. The study will cover a duration of 24 weeks, during which participants will have three hospital visits (at week 0, week 16 and week 24) and one telephone appointment (at week 8). These sessions will involve assessments of both physician and patient-reported disease severity, quality of life and the evaluation of dupilumab serum trough levels. Please refer below for a comprehensive overview of the outcome measures.

03

Conditions studied

  • Atopic Dermatitis
  • Atopic Dermatitis Eczema

Browse trials for

Keywords

  • Dupilumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is an adult,
  • Has a diagnosis of AE,
  • Receives dupilumab 300 mg q2w for the treatment of AE,
  • Has controlled disease according to the Treat-to-Target criteria,
  • Agrees to the possibility that the dosage of dupilumab will be lowered,
  • Has voluntarily signed and dated an prior to any study related procedure.

Exclusion criteria

Exclusion Criteria:

  • The subjects uses or initiates another systemic immunomodulating therapy for AE or another diagnosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
216 participants (estimated)

Study arms

  • Active comparator
    Dupilumab 300 mg q2w

    Dupilumab s.c. 300 mg every 2 weeks for 24 weeks.

    Drug: Dupilumab

  • Experimental
    Dupilumab 300 mg q3w

    Dupilumab s.c. 300 mg every 3 weeks for 24 weeks.

    Drug: Dupilumab

  • Experimental
    Dupilumab 300 mg q4w

    Dupilumab s.c. 300 mg every 4 weeks for 24 weeks.

    Drug: Dupilumab

Interventions

  • Administering Dupilumab 300 mg at different dosing intervals.

    Also known as: Dupixent

06

What researchers measure

Primary outcomes

  1. Mean EASI

    The mean EASI (Eczema Area and Severity Index). The EASI can range from 0 to 72, where a lower score indicates a better outcome.

    Time frame: 24 weeks

Secondary outcomes

  1. EASI

    The mean EASI (Eczema Area and Severity Index). The EASI can range from 0 to 72, where a lower score indicates a better outcome.

    Time frame: 16 weeks

  2. vIGA-AD

    The mean Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD). The vIGA-AD can range from 0 to 4, where a lower score indicates a better outcome.

    Time frame: 16 and 24 weeks

  3. PtGA

    The mean patient self-reported Global Assessment of disease severity (PtGA). The PtGA can range from 0 to 4, where a lower score indicates a better outcome.

    Time frame: 16 and 24 weeks

  4. NRS

    The mean Peak Pruritus Numerical Rating Scale (NRS). The NRS can range from 0 to 10, where a lower score indicates a better outcome.

    Time frame: 16 and 24 weeks

  5. POEM

    The mean Patient-Oriented Eczema Measure (POEM). The POEM can range from 0 to 28, where a lower score indicates a better outcome.

    Time frame: 16 and 24 weeks

  6. DLQI

    The mean Dermatology Life Quality Index (DLQI). The DLQI can range from 0 to 30, where a lower score indicates a better outcome.

    Time frame: 16 and 24 weeks

  7. RECAP

    The mean Recap of atopic eczema (RECAP). The RECAP can range from 0 to 28, where a lower score indicates a better outcome.

    Time frame: 16 and 24 weeks

  8. EQ-5D-5L

    The mean EuroQol-5 dimensions-5 level/Youth (EQ-5D-5L): adults and caregivers. The EQ-5D-5L can range from 0 to 1, where a higher score indicates a better outcome.

    Time frame: 16 and 24 weeks

  9. Adapted iMCQ

    Adapted iMTA Medical Consumption Questionnaire

    Time frame: 16 and 24 weeks

  10. Adapted iPCQ

    Adapted iMTA Productivity Cost Questionnaire

    Time frame: 16 and 24 weeks

  11. Adapted iVICQ

    Adapted iMTA Valuation of Informal Care Questionnaire

    Time frame: 16 and 24 weeks

  12. Dupilumab serum trough levels

    Dupilumab serum trough levels of 40 patients (n=20 in both the q3w and q4w arms)

    Time frame: 0 and 24 weeks

  13. Adverse events

    Number of adverse events of special interests (AEoSIs), severe adverse events, serious adverse events and suspected unexpected serious adverse reactions (SUSARs), categorized according to medical dictionary for regulatory activities (MedDRA)

    Time frame: 16 and 24 weeks

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.

Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 38 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Oct 2025 → Nov 2026 and completion Dec 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2023
First posted
Aug 22, 2023
StartActual
Aug 14, 2023
Primary completionEst.
Nov 5, 2026was Oct 2025
CompletionEst.
Dec 31, 2026was Dec 2025
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 29, 2026
Primary completion
Oct 1, 2025→Nov 5, 2026
Oct 29, 2026
Study completion
Dec 31, 2025→Dec 31, 2026
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Active, not recruiting
    Primary completion Oct 1, 2025→Nov 5, 2026
    Study completion Dec 31, 2025→Dec 31, 2026
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06004986
Collaborators
Erasmus Medical Center, Prothya Biosolutions
Responsible party
Prof. Dr. Phyllis I. Spuls (Prof. Dr. P.I. Spuls, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Aug 22, 2023
Start date
Aug 14, 2023
Primary completion
Nov 5, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 29, 2026

Study contacts

Louise AA Gerbens, MD PhD
study chair · Amsterdam UMC, location VUmc
Phyllis I Spuls, MD PhD
principal investigator · Amsterdam UMC, location VUmc
DirkJan Hijnen, MD PhD
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion